Drug intelligence / Profile preview

RGV-004

Development stage: Phase 1
Lead developer: Hangzhou Ronggu Biotechnology
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

RGV-004 is a genetically-engineered oncolytic vaccinia virus that expresses a CD19/CD3 bispecific antibody. It is administered intratumorally and is designed to target and replicate within cancer cells while simultaneously engaging the immune system against B-cell lymphomas. The virus selectively infects and lyses tumor cells, while the expressed bispecific antibody bridges CD19-expressing B-cell lymphoma cells with CD3-expressing T cells, potentially enhancing anti-tumor immune responses.

Targets

CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on RGV-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGV-004.

Explore the full profile